Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information from Kyowa Kirin Holdings B.V. - Mitomycin-C Kyowa 40 mg restricted to intravesical administration only for treatment of superficial bladder cancer
Important Safety Information - Mitomycin-C Kyowa 40 mg